Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Using two in vivo methods, microdialysis and rapid in situ electrochemistry, this study examined the modulation of extracellular glutamate levels by endogenously produced kynurenic acid (KYNA) in the prefrontal cortex (PFC) of awake rats. Measured by microdialysis, intraperitoneal (i.p.) administration of KYNA's bioprecursor L-kynurenine dose-dependently elevated extracellular KYNA and reduced extracellular glutamate (nadir after 50 mg/kg kynurenine: 60% decrease from baseline values). This dose-dependent decrease in glutamate levels was also seen using a glutamate-sensitive microelectrode array (MEA) (31% decrease following 50 mg/kg kynurenine). The kynurenine-induced reduction in glutamate was blocked (microdialysis) or attenuated (MEA) by co-administration of galantamine (3 mg/kg, i.p.), a drug that competes with KYNA at an allosteric potentiating site of the α7 nicotinic acetylcholine receptor. In separate experiments, extracellular glutamate levels were measured by MEA following the local perfusion (45 min) of the PFC with kynurenine (2.5 μM) or the selective KYNA biosynthesis inhibitor S-ethylsulfonylbenzoylalanine (S-ESBA; 5 mM). In agreement with previous microdialysis studies, systemic kynurenine application produced a reversible reduction in glutamate (nadir: −29%), whereas perfusion with S-ESBA increased glutamate levels reversibly (maximum: +38%). Collectively, these results demonstrate that fluctuations in the biosynthesis of KYNA in the PFC bi-directionally modulate extracellular glutamate levels, and that qualitatively very similar data are obtained by microdialysis and MEA. Since KYNA levels are elevated in the PFC of individuals with schizophrenia, and since prefrontal glutamatergic and nicotinic transmission mediate cognitive flexibility, normalization of KYNA levels in the PFC may constitute an effective treatment strategy for alleviating cognitive deficits in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Self-citationKrystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
The cognitive neuroscience of schizophrenia.
Barch, D. M. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143959 · Cited by 437
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426 · cited 1×
“This approach would be in line with recent clinical studies, which showed modest pro-cognitive effects in SZ patients treated with partial α7 nAChR agonists, positive α7 nAChR modulators such as galantamine (Schubert et al., 2006; Freedman et al., 2008; Thomsen et al., 2010) or various glutamatergic agonists (Coyle, 2…”
Cognitive Dysfunction in Schizophrenia: Convergence of γ-Aminobutyric Acid and Glutamate Alterations
Lewis, D. A., & Moghaddam, B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1372 · Cited by 404
Tan, H.-Y., Callicott, J. H., & Weinberger, D. R. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhm069 · Cited by 266
Nicotine Induces Glutamate Release from Thalamocortical Terminals in Prefrontal Cortex
Lambe, E. K., Picciotto, M. R., & Aghajanian, G. K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300032 · Cited by 261
Couey, J. J., Meredith, R. M., Spijker, S., Poorthuis, R. B., Smit, A. B., Brussaard, A. B., & Mansvelder, H. D. (2007) · Neuron · doi:10.1016/j.neuron.2007.03.006 · Cited by 253 · cited 1×
“Thus, the effect of KYNA on extracellular glutamate described here likely involves inhibition of heterogeneously distributed α7 nAChRs receptors - either within the PFC or in brain areas with reciprocal links to the PFC (Del Arco and Mora, 2005, 2008; Biton et al., 2007; Couey et al., 2007).”
Alkondon, M., Pereira, E. F. R., Eisenberg, H. M., & Albuquerque, E. X. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00066.2000 · Cited by 248
Leeson, V. C., Robbins, T. W., Matheson, E., Hutton, S. B., Ron, M. A., Barnes, T. R. E., & Joyce, E. M. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.05.016 · Cited by 219 · cited 1×
“, 2009) and cognitive flexibility (Leeson et al., 2009).”
Gioanni, Y., Rougeot, C., Clarke, P. B. S., Lepousé, C., Thierry, A. M., & Vidal, C. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00403.x · Cited by 191
Del Arco, A., & Mora, F. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.04.011 · Cited by 163
Quarta, D., Ferré, S., Solinas, M., You, Z., Hockemeyer, J., Popoli, P., & Goldberg, S. R. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02245.x · Cited by 163
Cortical Cholinergic Transmission and Cortical Information Processing in Schizophrenia
Sarter, M. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi006 · Cited by 153 · cited 2×
“There is also good evidence for cholinergic dysfunction in SZ (for reviews, see Hyde and Crook, 2001; Sarter et al., 2005), including reductions in the expression of nicotinic (Guan et al.”
Parikh, V., Man, K., Decker, M. W., & Sarter, M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5251-07.2008 · Cited by 127 · cited 1×
“, 1993; Vidal and Changeux, 1993) receptors, whereas subsequent work with genetic models and specific pharmacological agents provided convincing evidence that α4β2 nAChRs play a crucial role in nicotine-induced glutamate release in the PFC (Gioanni et al., 1999; Lambe et al., 2003; Parikh et al., 2008).”
Cited by
Neuroinflammation and depression: A review
Troubat, R., Barone, P., Leman, S., Desmidt, T., Cressant, A., Atanasova, B., Brizard, B., El Hage, W., Surget, A., Belzung, C., et al. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14720 · Cited by 1,107
Tryptophan-kynurenine pathway is dysregulated in inflammation and immune activation
Zou, M.-H. (2015) · Frontiers in Bioscience · doi:10.2741/4363 · Cited by 361
Blood-brain barrier permeability and physical exercise
Małkiewicz, M. A., Szarmach, A., Sabisz, A., Cubała, W. J., Szurowska, E., & Winklewski, P. J. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1403-x · Cited by 276
The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders
Stone, T. W., & Darlington, L. G. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12230 · Cited by 271
Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Sathyasaikumar, K. V., Stachowski, E. K., Wonodi, I., Roberts, R. C., Rassoulpour, A., McMahon, R. P., & Schwarcz, R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq112 · Cited by 253
Self-citation
Metadata
- Authors
- Konradsson-Geuken, Å., Wu, H. Q., Gash, C. R., Alexander, K. S., Campbell, A., Sozeri, Y., Pellicciari, R., Schwarcz, R., & Bruno, J. P.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 169
- Issue
- 4
- Pages
- 1848-1859
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W2042847268
- Cited by
- 93
- References
- 16
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.